Fc Engineered Anti-Human CD20 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ48] (CAT#: BioBet-C048ZP) Datasheet

Target
CD20
Isotype
Whole Human Antibody
Description
CDC-Enhanced Ocrelizumab is a Fc-modified anti-CD20 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Ocrelizumab, Ocrelizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Multiple sclerosis
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
FDA-approved

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
MS4A1
Full Name
membrane spanning 4-domains A1
Background
This gene encodes a member of the membranespanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a Blymphocyte surface molecule which plays a role in the development and differentiation of Bcells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
B1, S7, Bp35, CD20, CVID5, MS4A2, LEU-16,
Gene ID
Trade name
Ocrevus
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB11988
CAS number
637334-45-3
Antibody Isotype
Humanized IgG1
Description
Ocrelizumab, trade name Ocrvus, is a humanized anti-CD20 monoclonal antibody. It targets the CD20 marker on B lymphocytes and is therefore an immunosuppressive drug. It was developed by Genentech / Roche and was approved by the FDA in March 2017 for the treatment of multiple sclerosis.
Indication
Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)
UNII
A10SJL62JY

Ocrelizumab is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B lymphocytes that express the CD20 antigen. B lymphocytes are known to promote the pathogenesis of MS by activating pro-inflammatory T cells and secreting pro-inflammatory cytokines. Ocrelizumab promotes cytotoxicity of antibody-dependent cells and complement-mediated cell lysis by binding to CD20-expressing B lymphocytes. Ocrelizumab may induce antibody-dependent cytotoxicity, involving macrophages, natural killer cells, and cytotoxic T cells that work together to cause cell death.

Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK